APO-METHOTREXATE 2.5 MG — DIN 02182963
METHOTREXATE (METHOTREXATE DISODIUM) : 2.5 MG · APOTEX INC · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is APO-METHOTREXATE?
APO-METHOTREXATE 2.5 MG contains METHOTREXATE (METHOTREXATE DISODIUM) : 2.5 MG. It is listed in the Health Canada Drug Product Database under DIN 02182963, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 22-Jul-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is APO-METHOTREXATE used for?
APO-METHOTREXATE (methotrexate tablets) is indicated for Neoplastic diseases such as Choriocarcinoma, Acute Lymphoblastic Leukemia, Head and Neck Cancer, Metastasis of unknown primary, Burkitt's lymphoma, Advanced stages of childhood lymphoma (III and IV, St. Jude's Childrens' Research Hospital Staging System), and Advanced cases of mycosis fungoides (cutaneous T-cell lymphoma). It is also indicated as a Disease Modifying Antirheumatic Drug (DMARD) in severe disabling psoriasis/psoriatic arthritis, severe disabling rheumatoid arthritis (RA), and severe disabling seronegative arthritides where standard therapeutic interventions fail. In psoriasis, APO-METHOTREXATE should be restricted to severe recalcitrant, disabling psoriasis, which is not adequately responsive to other forms of therapy, and only when the diagnosis has been established after dermatologic consultation.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Methotrexate cost around the world?
Methotrexate is listed on 12 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Czechia | max producer price (ex-factory) | 9 | 77 | CZK███.██ |
| Australia | ex-manufacturer | 7 | 36 | AUD███.██ |
| Saudi Arabia | public | 19 | 33 | SAR███.██ |
| United States | acquisition | 3 | 27 | USD███.██ |
| Greece | producer price (ex-factory) | 23 | 23 | EUR███.██ |
| Austria | KVP (Kassenverkaufspreis) | 22 | 22 | EUR███.██ |
| Morocco | PPV (public price) | 8 | 17 | MAD███.██ |
| United Kingdom | hospital | 9 | 9 | GBP███.██ |
| Luxembourg | reimbursement | 9 | 9 | EUR███.██ |
| South Africa | single exit price | 7 | 7 | ZAR███.██ |
| Bahrain | retail (max) | 2 | 2 | BHD███.██ |
| United Arab Emirates | public | 1 | 1 | AED███.██ |
263 pack listings across 119 brand entries and 11 price bases, refreshed 08 Sep 2026. Ranges span every Methotrexate pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Methotrexate in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
16 holders have a Canadian DIN containing Methotrexate, across 51 DINs, of which 20 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| PHARMASCIENCE INC | 6 | 6 | METHOTREXATE INJECTION, BP, PMS-METHOTREXATE | Sourceable in Canada |
| PFIZER CANADA ULC | 7 | 5 | METHOTREXATE, METHOTREXATE INJECTION USP, METHOTREXATE SODIUM INJECTION USP, METHOTREXATE TABLETS, USP | Sourceable in Canada |
| ACCORD HEALTHCARE INC | 5 | 5 | ACH-METHOTREXATE, METHOTREXATE INJECTION BP | Sourceable in Canada |
| APOTEX INC | 2 | 1 | APO-METHOTREXATE, METHOTREXATE | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 2 | 1 | JAMP METHOTREXATE TABLETS, JAMP-METHOTREXATE | Sourceable in Canada |
| TEVA CANADA LIMITED | 2 | 1 | METHOTREXATE SODIUM INJECTION, RATIO-METHOTREXATE SODIUM | Sourceable in Canada |
| MANTRA PHARMA INC | 1 | 1 | M-METHOTREXATE | Sourceable in Canada |
| DAVID BULL LABORATORIES (PTY) LTD. | 6 | 0 | METHOTREXATE DBL INJ 10MG/ML, METHOTREXATE DBL INJ 2.5MG/ML, METHOTREXATE DBL INJ 25MG/ML, METHOTREXATE SOD INJ 25MG/ML USP, METHOTREXATE SODIUM INJ 25MG/ML USP, +1 more | No marketed DIN |
| LEDERLE CYANAMID CANADA INC. | 5 | 0 | METHOTREXATE SODIUM INJ 20MG, METHOTREXATE SODIUM INJ 25.0MG/ML, METHOTREXATE SODIUM INJ 25MG/ML, METHOTREXATE TAB 2.5MG, RHEUMATREX TAB 2.5MG | No marketed DIN |
| MEDEXUS PHARMACEUTICALS INC. | 5 | 0 | METOJECT | No marketed DIN |
| EUGIA PHARMA INC. | 2 | 0 | EUGIA-METHOTREXATE, EUGIA-METHOTREXATE TABLETS | No marketed DIN |
| WYETH-AYERST CANADA INC. | 2 | 0 | METHOTREXATE-LIQ IM IV IAR INT IVR 25MG/ML, METHOTREXATE-PWS IM IV IAR INT IVR 20MG/VIAL | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 2.5 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | bottles of 100 tablets and blister cartons of 24s |
| Storage | null |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Methotrexate |
|---|---|
| ATC code | L01BA01 |
| AHFS class | 10:00.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02182963 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2182963 |
| Brand name | APO-METHOTREXATE |
| Generic / active ingredient | METHOTREXATE (METHOTREXATE DISODIUM) : 2.5 MG |
| Market authorization holder | APOTEX INC |
| Health Canada schedule | Prescription |
| ATC code | L01BA01 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L01BA |
| Current status | MARKETED |
| Status date | 22-Jul-2021 |
| Original market date | 1999-09-17 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
Is Methotrexate in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by ACCORD HEALTHCARE INC, last seen 09 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
20 of 51 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACH-METHOTREXATE | 2.5 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | 02509067 |
| JAMP METHOTREXATE TABLETS | 10 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02553740 |
| M-METHOTREXATE | 2.5 MG | TABLET | MANTRA PHARMA INC | MARKETED | 02534916 |
| METHOTREXATE INJECTION BP | 25 MG | SOLUTION | ACCORD HEALTHCARE INC | MARKETED | 02464365 |
| METHOTREXATE INJECTION BP | 25 MG | SOLUTION | ACCORD HEALTHCARE INC | MARKETED | 02474735 |
| METHOTREXATE INJECTION BP | 25 MG | SOLUTION | ACCORD HEALTHCARE INC | MARKETED | 02327236 |
| METHOTREXATE INJECTION BP | 25 MG | SOLUTION | ACCORD HEALTHCARE INC | MARKETED | 02474891 |
| METHOTREXATE INJECTION USP | 25 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | 02182777 |
| METHOTREXATE INJECTION USP | 25 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | 02182955 |
| METHOTREXATE INJECTION USP | 10 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | 02182947 |
2 · Same class — other molecules in ATC L01BA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Methotrexate | ACH-METHOTREXATE · APO-METHOTREXATE · EUGIA-METHOTREXATE · EUGIA-METHOTREXATE TABLETS · +29 more | 51 | 20 | Yes |
| Pemetrexed | ACT PEMETREXED · ALIMTA · PEMETREXED · PEMETREXED DISODIUM FOR INJECTION · +4 more | 36 | 14 | Yes |
| Pralatrexate% | FOLOTYN | 2 | 1 | Yes |
| Raltitrexed | TOMUDEX | 1 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC L01B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| L01BC | Azacitidine · Capecitabine · Cytarabine · Decitabine · Decitabine, Combinations · +4 more | 112 | 34 |
| L01BB | Cladribine · Clofarabine · Fludarabine · Mercaptopurine · Nelarabine · +1 more | 18 | 10 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is APO-METHOTREXATE called?
The same molecule, Methotrexate, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| METOJECT PEN | Latin | Czechia |
| NORDIMET | Latin | Czechia |
| INJEXATE | Latin | Czechia |
| TREXAN NEO | Latin | Czechia |
| Trexject | Latin | Australia |
| DBL Methotrexate | Latin | Australia |
| INJEXATE AUTOINJEKTOR | Latin | Czechia |
| Metoject | Latin | Czechia, Saudi Arabia |
| FOXIEMO | Latin | Czechia |
| Chexate | Latin | Australia |
| Methoblastin | Latin | Australia |
| METHOTREXAT EBEWE | Latin | Czechia |
| Methotrexate Accord | Latin | Australia |
| METHOTREXATE BIODIM | Latin | Morocco |
| Methotrexate Ebewe | Latin | Australia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.